With the Brazil trials the only thing I don't like is the reduction to 350mg after the first dose in the severe trial. It's better to have the full power of leronlimab on display if needed then to not have it.

I especially like the primary outcome in the critical trial - cumulative proportion of clinical recovery. It's more nuanced then mortality and will showcase the differences between leronlimab and SOC even if death in the SOC arm has not occurred by 28 days.